SIGA Technologies (NASDAQ:SIGA) specializes in the development and commercialization of solutions for serious unmet medical needs, particularly in the area of biodefense. The company's most notable project is their flagship product, an antiviral drug designed to treat smallpox, a critical component in the strategic national stockpile for biodefense against potential bioterror threats. By focusing on the rapid deployment of their antiviral solutions, SIGA aims to address both government and commercial needs worldwide, enhancing public health preparedness. Their objectives include expanding the applications of their antiviral technology to cover additional infectious diseases, securing further contracts with governmental agencies, and reaching out to new international markets to solidify their presence in global public health defense.